Veritas In Silico

March 26, 2026

To Our Valued Shareholders;

Company Name: Veritas In Silico Inc.
Representative: Shingo NAKAMURA,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact Person: Tsuneo GODA,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

Report and Resolution at the 10th Annual General Shareholders' Meeting

Having successfully listed our shares on the Tokyo Stock Exchange Growth Market, Veritas In Silico Inc. (hereafter referred to as "the Company") will celebrate its 10th anniversary this coming November. The Company firmly believes that this significant milestone is attributable solely to the unwavering support it has received from all shareholders since its establishment, for which it expresses its deepest and most heartfelt gratitude.

The Corporate Philosophy, fueled by the utilization of aibVIS, proprietary mRNA-targeted drug discovery platform owned by the Company, is to "realize and foster a hope-filled and compassionate society where patients suffering from any disease will not have to abandon hope due to a lack of treatment, nor lament the unavailability of optimal care."

Since its inception, the Company has consistently dedicated itself to in-house research and development. Furthermore, the Company is currently collaborating with several pharmaceutical companies to advance small-molecule drug discovery. Since its IPO, the Company has also actively engaged in building its own pipeline. This commitment is a testament to its firm determination to contribute sustainably to society as a specialty pharmaceutical company in the future.

Upon reflection, it is notable that the Company did not hold a single patent at the time of its establishment. While it has since expanded its business and achieved a public listing, the Company keenly recognizes that it is still in a crucial phase where it must actively drive technological development forward. Spurred by this renewed mindset, all its executives and employees were greatly invigorated, leading to the filing of six new patent applications last fiscal year related to drug delivery systems and AI. The Company is resolute in its objective to achieve industry breakthroughs not only through AI but also through a variety of practical technologies.

The Company respectfully requests your continued and even greater support as it embarks on this journey forward.

The Company announces that the following matters have been reported and resolved at the 10th Annual General Shareholders' Meeting held on March 24, 2026.

Reported Matter Report on the Business Report, Financial Statements for the 10th Business Term (from January 1, 2025 to December 31, 2025), and the results of the audit on the Financial Statements by the Accounting Auditors and the Audit & Supervisory Board.

The Company has reported the matter.

Matter to be Resolved

Item 1: Election of 5 Directors

As the agenda item has been approved, 4 person has been re-elected: Shingo NAKAMURA, Hiroaki HAGIWARA, Isao KODA, *Kinichiro KOMINAMI. In addition, *Tomoko SATOH has been newly elected and appointed.

Item 2: Election of 1 Audit & Supervisory Board Member

As the agenda item has been approved, *Eiji HAMANO has been elected and appointed.

Item 3: Election of 1 Alternate Audit & Supervisory Board Member

As the agenda item has been approved, Jun GODA has been elected and appointed.

Furthermore, at the Board of Directors meeting held after the conclusion of the General Shareholders' Meeting, the Representative Director has been selected and assumed office as follows:

President and Representative Director: Shingo NAKAMURA

In addition, at the Board of Corporate Auditors meeting held after the conclusion of the General Shareholders' Meeting, the Full-time Corporate Auditor has been selected and assumed office as follows:

Full-time Corporate Auditor: Eiji HAMANO

As a result of these appointments, the Directors and Corporate Auditors as of March 24, 2026, are as follows:

President and Representative Director	Shingo NAKAMURA
Director	Hiroaki HAGIWASRA
Director	Isao KODA
Director	Kinichiro KOMINAMI
Director	Tomoko SATOH (Newly appointed)
Full-time Audit & Supervisory Board Member	Eiji HAMANO (Newly appointed)
Audit & Supervisory Board Member	Minoru HIROOKA
Audit & Supervisory Board Member	Minako WAKABAYASHI

(Notes)

1. Directors Kinichiro Kominami and Tomoko Sato are Outside Directors, and are Independent Officers as stipulated by the Tokyo Stock Exchange.
2. Full-time Corporate Auditor Eiji Hamano, and Corporate Auditors Yutaka Hirooka and Minako Wakabayashi are Outside Corporate Auditors, and are Independent Officers as stipulated by the Tokyo Stock Exchange.

END